Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP3772 Phase 1 Study in Japanese Adults and Elderly
NCT04265911Phase 1Completed
- Sponsor
- Affinivax, Inc.
- Start
- Feb 2020
- Primary completion
- Nov 2020
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of AFX3772 in pneumococcal disease (6 arms), sponsored by Affinivax, Inc. Primary endpoints: Treatment Emergent Adverse Events at Day 30, Vital Sign Abnormalities and/or Adverse Events at Day 30 and 4 more. Started Feb 2020; status: completed.
02
Drugs
AFX3772
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on NCT04265911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04265911.